科研之友
微信
新浪微博
Facebook
分享链接
摘要
In the adjuvant setting for malignant melanoma, interferon (IFN)--2b and pegylated (PEG) IFN--2b were approved in several countries including the USA before these were approved in Japan. To resolve the drug-lag issue, this phase I study was designed to evaluate the safety and tolerability in Japanese patients with stage II or III malignant melanoma who had undergone surgery, by treating with PEG IFN--2b. As with a previously reported phase III study, patients were to receive PEG IFN--2b 6 g/kg per week s.c. during an 8-week induction phase, followed by a maintenance phase at a dose of 3 g/kg per week up to 5 years. Dose-limiting toxicity and pharmacokinetics were assessed during the initial 8 weeks. Of the nine patients enrolled, two patients had dose-limiting toxicities that resolved after discontinuation of treatment. The most frequently reported drug-related adverse events (DRAE) included pyrexia, decreased neutrophil and white blood cell counts, and arthralgia. Grade 3 DRAE included decreased neutrophil count. No deaths, serious adverse events and grade 4 adverse events were reported. Distant metastasis occurred in one patient. No apparent differences in area under the concentration-time curve and maximum observed serum concentration were observed between Japanese and historical non-Japanese pharmacokinetic data, suggesting no marked racial differences. No neutralizing antibody was detected in these patient samples. PEG IFN--2b was tolerated in Japanese patients, and eventually approved in Japan in May 2015 for adjuvant therapy in patients with stage III malignant melanoma. Because the number of patients was limited, further investigation would be crucial.
- 出版日期2016-10
